{"paper_id":"29632477-7c32-4473-a181-fc7598099532","body_text":"Abstract\nObjective\nTo investigate the potential malignant characteristics and pathogenesis of endometriosis as well as the role of human growth hormone and epidermal growth factor receptor in the pathogenesis of malignant transformation of endometriosis.\nMethods\nThe immunohistochemical S-P method was used to examine the expression of human growth hormone and epidermal growth factor receptor in the eutopic and ectopic endometrium of 84 cases of endometriosis.\nResults\nThe percentage of positive cases of human growth hormone in eutopic and ectopic endometrium was 90.77% (59/65) and 85.71% (72/ 84) respectively. The percentage of positive cases of epidermal growth factor receptor in eutopic and ectopic endometrium was 81.54% (53/65) and 89.29% (75/84) respectively. The positive rate of epidermal growth factor receptor in ectopic endometrium was higher than that in the eutopic endometrium but without a statistically significant difference (P> 0.05).\nConclusion\nEndometriosis is caused by multiple factors, which possesses some biologic features of neoplastic tissue such as invasion and metastasis. Both human growth hormone and epidermal growth factor receptor are highly expressed in eutopic and ectopic endometrium, which lead directly or indirectly to the pathogenesis of endometriosis and promote the initiation and malignant transformation of endometriosis.\nSimilar content being viewed by others\nReferences\nOta H, Maki M, Shidara Y, et al. Effects of danazol at the immunologic level in patients with adenomyosis with special reference to autoantibodies: A multi-center cooperative study. Am J Obstet Gynecol. 1992; 167: 481–486.\nZong LL, Ma L, Wang XN, et al. Expression of heparanase gene in eutopic and ectopic endometrium of women with endometriosis. Chin J Obstet Gynecol. 2004; 39: 24–26.\nGiudice LC, Tazuke SI, Swiersz L. Status of current research on endometriosis. J Reprod Med. 1998; 43: 252\nVarma R, Rollason T, Janesh KG, et al. Endometriosis and the neoplastic process. Reproduction. 2004; 127: 293–304.\nGarry R. The endometriosis syndromes: a clinical classification in the presence of aetiological confusion and therapeutic anarchy. Hum Reprod. 2004; 19: 760–768.\nCamran N, Fair N. A simplified method of laparoscopic presacral neurectomy for the treatment of central Pelvic pain due to endometriosis. British J Obstet Gynaecol. 1992; 99: 659–663.\nGuo LN, Liu TH, Lang JH. The malignant potential study of ovarian atypical endometriosis. Chin J Pathol. 2001; 30: 271–274.\nHerbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002; 20: 3815–3825.\nBiscardi JS, Ishizawar RC, Silva CM, et al. Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c -Src interactions in breast cancer. Breast Cancer Res. 2000; 2: 203–210.\nWang Q, Lin ZY, Feng XL. Alterations in metastatic properties of hepatocellular carcinoma cell following liras oncogene transfection. World J Gastroenterol. 2001; 7: 335–339.\nLeyendecker G, Herbertz M, Kunz G, et al. Endometriosis results from the dislocation of basal endometrium. Hum Reprod. 2002; 17: 2725–2736.\nHuang JC, Yeh J. Quantitative analysis of epidermal growth factor gene expression in endometriosis. J Clin Endocrinol Metab. 1994; 79: 1097–1101.\nAnaf V, Simon P, Fayt I, et al. Smooth muscles are frequent components of endometriotic lesions. Hum Reprod. 2000; 15: 767–771.\nLeyendecker G. Endometriosis is an entity with extreme pleiomorphism. Hum Reprod. 2000; 15: 4–7.\nOstrenski A. Extensive introgenic adenomyosis after laparoscopic myomectomy. Fertil Steril. 1998; 69:143–145.\nKumar V, Cotran RS. Basic Pathology. 7th ed, Print, in Beijing, Peking University Medical Press. 2003; 689.\nKennedy S. The genetics of endometriosis. J Reprod Med. 1998; 43: 263–268.\nJones RK, Bulmer JN, Searle RF. Immunohistochemical characterization of proliferation, oestrogen receptor and progesterone receptor expression in endometriosis: comparison of eutopic and ectopic endometrium with normal cycling endometrium. Hum Reprod. 1995; 10: 3272–3279.\nMa JJ. The association of PTEN tumor suppressor gene in the malignant transformation of endometriosis. Foreign Med Sci Obstet Gynecol Sec. 2004; 31: 308–311.\nJacqueline SB, Rumey CI, Corinne MS. Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c -Src interactions in breast cancer. Breast Cancer Res. 2000; 2: 203–210.\nBoonstra J, Rijken P, Humbel B, et al. The epidermal growth factor. Cell Biol Int. 1995; 19: 413–430.\nChoi YM, Ku SY, Lee JY. The effects of sex steroids and growth factor on the proliferation of human endometrial stromal cells. Korean J Obstet Gynecol. 1996; 39: 679–687.\nIgnar-Trowbridge DM, Nelson KG, Bidwell MC, et al. Coupling of dual signalling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci. 1992; 89: 4658–4662.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nAbout this article\nCite this article\nWang, C., Zhou, H., You, X. et al. An investigation of the potential malignant characteristics of endometriosis. Chin. J. Clin. Oncol. 2, 861–865 (2005). https://doi.org/10.1007/BF02789655\nReceived:\nAccepted:\nIssue date:\nDOI: https://doi.org/10.1007/BF02789655","source_license":"CC0","license_restricted":false}